

Novel and Emerging Therapeutic Strategies in the Management of Hematologic Disorder-Related Anemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following statements is true regarding the Phase III MEDALIST study investigating luspatercept in the treatment of anemia?
 - a. Eligible patients included those with high-risk MDS
 - b. No new safety signals were identified in the luspatercept arm
 - c. About 40% of patients who received luspatercept attained RBC transfusion independence
 - d. All of the above
 - e. Both b and c
 - f. Both a and c
2. Sotatercept has demonstrated activity in the treatment of anemia associated with which of the following diseases?
 - a. Myelofibrosis
 - b. Thalassemia
 - c. MDS
 - d. All of the above
3. The ongoing Phase II BEYOND study is evaluating the efficacy and safety of luspatercept in adult patients with beta thalassemia who _____ transfusion dependent.
 - a. Are
 - b. Are not
4. The BELIEVE trial demonstrated significant reductions in RBC transfusion burden with luspatercept in comparison to placebo for adult patients with transfusion-dependent beta thalassemia.
 - a. True
 - b. False
5. Which of the following statements most accurately describes the mechanism of action of luspatercept?
 - a. It inhibits VEGF receptors
 - b. It inhibits several ligands in the TGF-beta superfamily
 - c. It is an inhibitor of JAK1/2
6. The TELESTO trial evaluating deferasirox versus placebo for patients with low- or intermediate-1-risk MDS _____ its composite primary endpoint of time to death or first nonfatal event associated with cardiac or liver function or transformation to acute myeloid leukemia.
 - a. Met
 - b. Did not meet
7. Which of the following statements is true regarding the splicing factor SF3B1 gene mutation?
 - a. It is associated with benefit from luspatercept
 - b. It occurs with high frequency in patients with anemia with ring sideroblasts
 - c. It is associated with adverse outcomes among patients with MDS
 - d. All of the above
 - e. Both a and b
8. The ongoing Phase III COMMANDS trial is comparing _____ to an erythropoietin-stimulating agent for the treatment of anemia associated with MDS.
 - a. Luspatercept
 - b. Sotatercept
 - c. Aflibercept
9. Which of the following drug types best reflects the mechanism of action of PRM-151?
 - a. Antifibrotic immunomodulator
 - b. JAK2 inhibitor
 - c. PI3-kinase inhibitor
10. The JAK2/FLT3 inhibitor pacritinib does not confer significant benefit in terms of reduction in spleen volume and improvement in constitutional symptoms for patients with myelofibrosis and thrombocytopenia.
 - a. True
 - b. False